Rogerio Vivaldi, Sigilon CEO (Sigilon via website)
As Bob Langer biotech's lead cell therapy remains on FDA hold, researchers find 'unexpected' fibrosis
Back in July, the FDA placed a clinical hold on the Bob Langer and Flagship-backed biotech Sigilon Therapeutics for its lead program to treat …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
